Genetic testing embryos pgt Risks & Side Effects Explained by Surgeons

Genetic testing embryos PGT risks are generally low when testing is performed by an experienced IVF and genetics laboratory team, but no procedure is completely risk-free. The main considerations are the small possibility of harm to an embryo from biopsy, inconclusive or inaccurate findings, and the emotional and practical impact of having fewer embryos available for transfer.

Overview: What Are Genetic Testing Embryos PGT Risks?

Genetic testing embryos PGT risks are usually considered low, especially compared with the potential benefit for people who have a known inherited genetic condition or an increased likelihood of chromosome-related embryo abnormalities. However, PGT is not risk-free and does not provide certainty about every aspect of an embryo’s health. It is a laboratory test used alongside in vitro fertilisation (IVF), not a replacement for standard pregnancy care.

Preimplantation genetic testing (PGT) involves creating embryos through IVF, removing a few cells for analysis, and freezing the embryos while results are reviewed. Depending on the reason for testing, PGT may look for a specific inherited condition (PGT-M), chromosome rearrangements (PGT-SR), or chromosome number differences (PGT-A). Learn more about genetic testing of embryos with PGT.

The potential risks come from several parts of the process: IVF medication and egg collection, embryo biopsy, freezing and thawing, and the interpretation of genetic results. A careful discussion with fertility and genetics professionals helps place these risks in context and supports informed decision-making.

How PGT Works and What It Can Test

PGT is performed in an IVF laboratory. Eggs are collected after ovarian stimulation and fertilised with sperm. The resulting embryos develop in culture for several days. When an embryo reaches the blastocyst stage, a trained embryologist removes a small sample of cells from the trophectoderm, the outer cell layer that largely contributes to the placenta.

The sampled cells are sent to a genetics laboratory. PGT-M is designed for families with a known single-gene condition, such as certain inherited blood, nerve, or metabolic disorders. PGT-SR may be considered when one partner carries a chromosome rearrangement. PGT-A assesses whether there are more or fewer chromosomes than expected, a finding that can affect implantation and miscarriage risk.

Testing is targeted and has limits. PGT does not routinely assess every possible genetic condition, birth difference, developmental concern, or health condition that may occur later in life. The test used, the family history, and the quality of DNA available from the biopsy all affect what information can be provided.

Who May Consider PGT?

PGT may be discussed with people who have a known genetic condition, carry a genetic variant that could be passed to a child, or have a family history suggesting a significant inherited condition. It can also be considered for couples in which one partner has a balanced chromosome rearrangement. Genetic counselling is particularly important in these situations because testing usually needs to be tailored to the family’s specific finding.

Some IVF patients may ask about PGT-A after repeated miscarriage, repeated unsuccessful embryo transfers, or with increasing maternal age. Whether it is helpful varies from person to person. It may not improve outcomes for every patient, particularly when only a small number of embryos are expected, because testing can identify no embryos suitable for transfer in a given cycle.

A fertility specialist considers age, ovarian reserve, semen factors, reproductive history, family history, genetic test results, and personal priorities. PGT requires IVF even when infertility is not otherwise present. The decision should include discussion of alternatives, such as conceiving without PGT and using prenatal testing during pregnancy, donor eggs or sperm, adoption, or choosing not to pursue pregnancy.

Step by Step: From IVF to Embryo Transfer

The process begins with fertility assessment and, when indicated, genetic counselling. For PGT-M or PGT-SR, the laboratory may need time before treatment starts to develop or validate a test specific to the family. This preparation is important for accuracy and may involve reviewing genetic reports from affected relatives where available.

During an IVF cycle, ovarian stimulation medicines encourage several eggs to mature. Eggs are collected through a minor procedure, usually with sedation, and are fertilised in the laboratory. Embryos are monitored as they develop. On about day five, six, or sometimes seven, suitable blastocysts undergo biopsy. The biopsied embryos are commonly frozen while testing takes place.

Once results are available, the fertility team discusses which embryos may be considered for transfer based on the testing method and embryo development. A frozen embryo transfer can then be planned in a later cycle. The biopsy itself does not cause a noticeable recovery period because it is performed on the embryo in the laboratory; recovery for the patient mainly relates to egg collection and, later, any embryo transfer medicines.

• Consultation, fertility evaluation and genetic counselling
• Ovarian stimulation and monitoring
• Egg collection and laboratory fertilisation
• Blastocyst biopsy, embryo freezing and genetic analysis
• Review of results and planning for frozen embryo transfer

Risks, Side Effects and Important Limitations

For the person undergoing treatment, the main physical side effects are related to IVF rather than the genetic test itself. Ovarian stimulation can cause bloating, pelvic discomfort, mood changes, headaches, and bruising at injection sites. Egg collection may cause temporary cramping, spotting, or fatigue. Rare complications include infection, bleeding, anaesthetic reactions, or ovarian hyperstimulation syndrome, which requires prompt medical assessment.

Embryo biopsy is generally performed using established laboratory techniques, but it may rarely affect embryo survival or developmental potential. Freezing and thawing are also highly developed processes, yet a small number of embryos may not survive warming. It can be difficult to separate the effects of biopsy from the embryo’s underlying developmental potential, since embryos with chromosome or developmental differences may be less likely to continue developing regardless of testing.

PGT results can be inconclusive when there is insufficient or poor-quality DNA. A result may also show mosaicism, meaning sampled cells appear to have different chromosome patterns. Because a biopsy samples only a few cells, it may not fully represent every cell in the embryo. Interpretation of mosaic results is complex and should be discussed with a reproductive genetics specialist.

Although laboratories use strict quality controls, technical or human errors are possible. PGT may also not detect genetic changes outside the scope of the test. For these reasons, professional organisations advise discussing prenatal screening and, in some circumstances, diagnostic tests such as chorionic villus sampling or amniocentesis during pregnancy. These tests have different purposes, timing, and risks, which an obstetrician or genetic counsellor can explain.

Benefits, Emotional Considerations and Recovery Timeline

For appropriate candidates, PGT can help identify embryos that are unlikely to have a particular known inherited condition or a tested chromosome finding. This information may reduce the likelihood of transferring an affected embryo and can support reproductive planning. It may also help some patients avoid a pregnancy affected by a serious familial genetic disorder, though the outcome depends on the condition, test type, and embryos available.

There are meaningful emotional considerations. Waiting for results, learning that few or no embryos are suitable for transfer, and deciding what to do with embryos can be stressful. Individuals and couples may benefit from genetic counselling, fertility counselling, and mental health support before and during treatment. There is no single “right” decision; choices should reflect the patient’s values, beliefs, medical circumstances, and future family plans.

After egg collection, many people return to usual light activities within one or two days, though recovery varies. Bloating and discomfort generally improve over several days. The interval from biopsy to results varies by laboratory and test type, and embryo transfer is often scheduled in a subsequent menstrual cycle. The fertility team can provide personalised guidance on activity, medicines, and timing.

When to Seek Medical Care

Urgent medical advice is needed after IVF egg collection for severe or worsening abdominal pain, heavy bleeding, fainting, shortness of breath, chest pain, persistent vomiting, fever, rapidly increasing abdominal swelling, or a marked reduction in urination. These symptoms are uncommon but may indicate complications such as bleeding, infection, or ovarian hyperstimulation syndrome.

Patients should also contact their fertility clinic if they are unsure how to take prescribed medicines, have significant emotional distress, or need clarification about PGT findings. Genetic results can be complex, and decisions about embryo transfer should not be rushed without appropriate counselling.

Acibadem International’s multidisciplinary fertility, embryology, obstetric, and genetics specialists in JCI-accredited hospitals support international patients who are considering IVF and PGT. A qualified fertility specialist can explain individual risks, the expected pathway, and suitable follow-up during pregnancy.

Frequently asked questions

Is genetic testing of embryos during IVF safe?

PGT is widely used and embryo biopsy is generally considered low risk when carried out by an experienced IVF laboratory. However, there is a small possibility that biopsy, freezing, or thawing may affect an embryo, and results can sometimes be inconclusive. The physical risks for the patient are mainly those associated with IVF medicines and egg collection.

Can PGT damage an embryo?

A few cells are removed from the outer layer of a blastocyst, which is expected to contribute largely to the placenta. Most embryos tolerate biopsy, but damage or reduced developmental potential cannot be ruled out completely. Not every embryo survives culture, freezing, or thawing, whether or not PGT is used.

Does PGT guarantee a healthy baby?

No. PGT reduces the chance of the specific genetic or chromosome finding that has been tested for, but it cannot test for every health condition or developmental difference. Prenatal care remains important, and a clinician may discuss prenatal screening or diagnostic testing after pregnancy is established.

What does a mosaic PGT result mean?

A mosaic result means that the tested sample showed cells with different chromosome patterns. Because only a small number of cells are analysed, the result may not represent the entire embryo. A reproductive genetic counsellor and fertility specialist can explain what the specific finding may mean and whether transfer could be considered.

How long does recovery take after PGT?

The embryo biopsy is done in the laboratory, so it does not create a physical recovery period for the patient. Recovery relates mainly to egg collection, after which mild cramping, bloating, or tiredness often improves within several days. The clinic should be contacted for severe pain, heavy bleeding, breathing difficulty, or rapidly worsening swelling.

Who should have genetic counselling before PGT?

Genetic counselling is particularly valuable for anyone with a known genetic condition, a family history of an inherited disorder, or a chromosome rearrangement. It is also helpful for people considering PGT-A, as the benefits and limitations depend on individual fertility circumstances. Counselling explains what the test can and cannot answer and reviews alternatives.

References

• American College of Obstetricians and Gynecologists
• American Society for Reproductive Medicine
• European Society of Human Reproduction and Embryology
• Human Fertilisation and Embryology Authority
• Centers for Disease Control and Prevention

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.